Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC)

Seregni, Ettore; Foa, P.; Bogni, A.; Botti, Claudio; Cataldo, Ignazio; Sala, M.; Mezzetti, Maura; Gasparini, M; Santambrogio, Luigi; Legnani, D.; Bombardieri, Emilio

doi:10.3892/or.3.1.95

Cited by 7 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, discrepancies are observed with cytologic analysis in more than 15% of the patients, thereby indicating the need to improve the histological diagnosis. CYFRA is 1 of the most sensitive tumor markers available, although in our experience, as well as that of most publications, there is no clear relationship with histology [15,17,[19][20][21][22][24][25][26] . CEA is mainly found in adenocarcinomas but is unable to discriminate between SCLC and NSCLC [9,20,[25][26]29] .…”

Section: Mucins As Tumor Markers In Lung Cancermentioning

confidence: 84%

“…By contrast, a high number of tumor markers have been studied in NSCLC, including CEA, cytokeratins (CYFRA, TPA, TPS), mucins (CA 125) and SCC, but not all are specific for lung cancer and so they may also be found in other malignancies [14,25,37,[40][41][44][45][46] . The use of different combinations of tumor markers has been suggested, although no specific combination has been well established [9,15,17,[19][20][21][22][24][25][26] . Similar to previous studies, our results confirm that CYFRA 21-1 and CEA are the most sensitive tumor markers in NSCLC [15,17,[19][20][21][22][24][25][26] .…”

Section: Discussionmentioning

confidence: 99%

“…The use of different combinations of tumor markers has been suggested, although no specific combination has been well established [9,15,17,[19][20][21][22][24][25][26] . Similar to previous studies, our results confirm that CYFRA 21-1 and CEA are the most sensitive tumor markers in NSCLC [15,17,[19][20][21][22][24][25][26] . Mucins such as TAG-72.3, CA 15.3 or CA 19.9 have rarely been studied in lung cancer and their positivity is mainly suggestive of breast, gynecolog- Other patterns not used in the classification (NSCLC) SCC >1.5 ng/ml and NSE <35 ng/ml 90/92 (97.8) Stage I-III TAG-72.3 >10 ng/ml and NSE <35 ng/ml 27/28 (96.4) CA 125 >75 U/ml and NSE <35 ng/ml 35/37 (94.6) CA 19.9 U/ml and NSE <35 ng/ml 38/40 (95) Stage IV TAG-72.3 >10 ng/ml and NSE <45 ng/ml 70/70 (100) CA 125 >75 U/ml and NSE <45 ng/ml 97/100 (97) CA 19.9 U/ml and NSE <45 ng/ml 82/85 (96.5)…”

Section: Discussionmentioning

confidence: 99%

“…Tumor marker sensitivity is important in 2 different ways: first in relation to the diagnosis and second in the follow-up. Tumor markers are mostly useful in therapy monitoring, mainly in those patients with abnormal tumor marker serum levels [9,17,22,25,27,30] . NSE is the tumor marker of choice in SCLC, although sensitivity may be increased with the inclusion of CEA and/or CYFRA 21-1 and this combination is considered the most effective.…”

Section: Mucins As Tumor Markers In Lung Cancermentioning

confidence: 99%

“…Nonetheless, several tumor markers such as CEA and SCC as well as cytokeratins including CYFRA 21-1, TPA or TPS are used in this disease [11][12][13][14][15][16][17][18][19][20] . Most publications report that a combination of several tumor markers provides a high sensitivity, although the most useful combination remains unclear [18,[21][22][23][24][25][26] . The most accepted clinical use of tumor markers in lung cancer is in the follow-up, with contradictory results in relation to their prognostic or predictive value [19,[27][28][29][30][31] .…”

mentioning

confidence: 99%

See 4 more Smart Citations

Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as Tumor Markers in Patients with Lung Cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE

Molina¹,

Augé²,

Escudero³

et al. 2008

Tumor Biol

108

View full text Add to dashboard Cite

Tumor marker serum levels were prospectively studied in 289 patients with suspected, but unconfirmed, lung cancer and in 513 patients with lung cancer [417 non-small cell lung cancer (NSCLC) patients and 96 small cell lung cancer (SCLC) patients]. In patients with benign disease, abnormal serum levels were found for the following tumor markers: CEA (in 6.6% of patients); CA 19.9 (6.2%); CA 125 (28.7%); NSE (0.7%); CYFRA (8.7%); TAG-72.3 (4.2%); SCC (3.5%), and CA 15.3 (3.5%). Excluding patients with renal failure or liver diseases, tumor marker specificity improved with abnormal levels in 0.5% for NSE, 0.9% for SCC, 2.8% for CEA, CA 15.3 and TAG-72.3, 3.8% for CA 19.9, 4.2% for CYFRA and 21.4% for CA 125. Excluding CA 125, one of the markers was abnormal in 15% of patients without malignancy. Tumor marker sensitivity was related to cancer histology and tumor extension. NSE had the highest sensitivity in SCLC and CYFRA and CEA in NSCLC. Significantly higher concentrations of CEA, SCC, CA 125, CA 15.3 and TAG-72.3 were found in NSCLC than in SCLC. Likewise, significantly higher CEA (p < 0.0001), TAG-72.3 (p < 0.001), CA 15.3 (p < 0.0001) and CA 125 (p < 0.01) were found in adenocarcinomas than in squamous tumors. Using a combination of 3 tumor markers (CEA, CYFRA 21-1 in all histologies, SCC in squamous tumors and CA 15.3 in adenocarcinomas), a high sensitivity may be achieved in all histological types. Tumor markers may be useful in the histological differentiation of NSCLC and SCLC. Using specific criteria for the differentiation of SCLC and NSCLC, the sensitivity was 84.2 and 68.8%, the specificity was 93.8 and 99.7%, the positive predictive value was 98.3 and 98.5% and the negative predictive value was 57.7 and 93.3%, respectively.

show abstract

Section: Mucins As Tumor Markers In Lung Cancermentioning

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Mucins As Tumor Markers In Lung Cancermentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as Tumor Markers in Patients with Lung Cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE

Molina¹,

Augé²,

Escudero³

et al. 2008

Tumor Biol

108

View full text Add to dashboard Cite

show abstract

Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer

et al. 2019

View full text Add to dashboard Cite

Background Lung cancer has the highest fatality rate of all cancer types. To improve patients’ survival and life quality, it is therefore very important to screen for and detect it at an early stage. Methods A negative enrichment–fluorescence in situ hybridization (NE‐FISH) approach was used to detect circulating tumor cells (CTCs) in lung cancer patients, and levels of lung cancer‐associated serum markers were also measured in the peripheral blood of these same patients. The correlation between CTCs, serum cancer markers (carcinoembryonic antigen [CEA], CA 125, CYFRA 21‐1, and SCC), and clinicopathological characteristics was then investigated. Moreover, the potential clinical use of the combination of CTCs and tumor markers for the diagnosis of lung cancer, especially at early stages, was also explored. Results CTC frequencies in lung cancer patients were significantly higher than in healthy control volunteers or patients with benign lung disease, and the area under the receiver operating characteristics curve for the control group was 0.846 (95% CI 0.796‐0.887, P < 0.001). The rate of CTC positivity in lung cancer patients was 68.29% when the CTC cutoff value was 2, and the sensitivity of this means of lung cancer detection rose to 82.93% by combining CTC‐based detection with measurements of serum tumor markers. Similarly, the diagnostic sensitivity of this approach in early‐stage lung cancer patients (I‐II) was improved from 63.93% to 78.69%. Detection of CTCs can thus assist with the identification of benign and malignant pulmonary nodules. Conclusions It is potentially helpful and effective to employ a combination of CTCs and serum tumor markers for the clinical diagnosis of lung cancer.

show abstract

Intérêt clinique du dosage sérique du tissue polypeptide antigen

Bugugnani

1997

Immuno-analyse & Biologie Spécialisée

View full text Add to dashboard Cite

Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC)

Cited by 7 publications

References 0 publications

Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as Tumor Markers in Patients with Lung Cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE

Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as Tumor Markers in Patients with Lung Cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE

Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer

Intérêt clinique du dosage sérique du tissue polypeptide antigen

Contact Info

Product

Resources

About